Media Coverage

Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others. Take a look at the latest Evaluate and Vantage coverage.

If you have questions about Evaluate or require data and expert insights to help support your editorial content, please see our Media Contacts.

Latest Media Coverage

Nature Reviews Drug Discovery

FDA new drug approvals in Q3 2019

The biggest approval of the third quarter was not a new drug, but an oral version of Novo Nordisk’s semaglutide, branded Rybelsus, which has a consensus sales forecast of…

Browse the archive

The Pharma Letter

Look back at pharma news in the week to August 30

In paying $25 million up front to license Ionis Pharmaceuticals’ chronic hepatitis B antisense therapies GlaxoSmithKline looks to have cut a better deal than Johnson…

The Pharma Letter

Look back at pharma news in the week to August 24

Coming in the wake of news of a substantial delay to its gene therapy project, SRP-9001, which was then hit by a safety scare a couple of days later, it is little wonder…

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.